- (-%)
Source:
We are a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Our initial focus is on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy ("DCM") ("BAG3 DCM"). BAG3 DCM is a heritable rare disease that leads to early onset, rapidly progressing heart failure and significant mortality and morbidity.
Country | United States |
Headquarters | cambridge, massachusetts |
Phone Number | 610-424-2650 |
Industry | finance |
CEO | Magdalene Cook, M.D. |
Website | renovacor.com |